Why the study?
Is urinary angiotensinogen increased in hypertensive patients and modulated by RAS blockers?
Population
106 adults. Excluded: estimated glomerular filtration levels <30 mL/min per 1.73 m.
Comparison
Hypertension vs Normotensive subjects
Design
Cross-sectional
Authors
Loading...
May support UAGT as intrarenal RAS biomarker in hypertension; hypothesis-generating and should not yet change practice.
Is urinary angiotensinogen increased in hypertensive patients and modulated by RAS blockers?
Urinary angiotensinogen is elevated in hypertensive patients and suppressed by RAS blockers, suggesting its utility as a biomarker for assessing intrarenal RAS activity.
Kobori et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: